A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499

Life Sciences

Volumn 120, Issue , 2015, Pages 1-7

  Byun, Soo Young ^a   Shin, Young June ^b   Nam, Ky Youb ^c   Hong, Sung Pyo ^a   Ahn, Soon Kil ^a  

^a SolarLight Ltd   (South Korea)

^b Central R and D   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

11 HSD1 inhibitor; blood glucose; glucocorticoid; KKAy mice; metabolic syndrome; type 2 diabetes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 4 (1 ((2 FLUORO N METHYLPHENYLSULFONAMIDO)METHYL) CYCLOPROPANECARBOXAMIDO)ADAMANTANE 1 CARBOXAMIDE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; OXIDOREDUCTASE INHIBITOR; PIOGLITAZONE; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG; 4-(1-((2-FLUORO-N-METHYLPHENYLSULFONAMIDO)METHYL)CYCLOPROPANECARBOXAMIDO)ADAMANTANE-1-CARBOXAMIDE; ADAMANTANE; ENZYME INHIBITOR; GLUCOCORTICOID; GLUCOSE BLOOD LEVEL; SULFONAMIDE;

3T3 CELL LINE; ADIPOCYTE; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; EPIDIDYMIS FAT; EX VIVO STUDY; GLUCOSE BLOOD LEVEL; HAPLORHINI; HUMAN; IC50; IN VITRO STUDY; LIVER MICROSOME; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CHEMISTRY; CYTOLOGY; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; TREATMENT OUTCOME;

ANIMALIA; MUS;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 3T3 CELLS; ADAMANTANE; ADIPOCYTES; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; ENZYME INHIBITORS; GLUCOCORTICOIDS; HAPLORHINI; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84918535122     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2014.11.001     Document Type: Article

References (38)

1. P. Alberts, C. Nilsson, G. Selen, L.O. Engblom, N.H. Edling, and S. Norling Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains Endocrinology 144 2003 4755 4762
2. P. Anagnostis, N. Katsiki, F. Adamidou, V.G. Athyros, A. Karagiannis, and M. Kita 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism 62 2013 21 33
3. R.C. Andrews, O. Rooyackers, and B.R. Walker Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes J. Clin. Endocrinol. Metab. 88 2003 285 291
4. R.C. Andrews, and B.R. Walker Glucocorticoids and insulin resistance: old hormones, new targets Clin. Sci. (Lond.) 96 1999 513 523
5. T. Barf, J. Vallgarda, R. Emond, C. Haggstrom, G. Kurz, and A. Nygren Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 J. Med. Chem. 45 2002 3813 3815
6. B.G. Bhat, N. Hosea, A. Fanjul, J. Herrera, J. Chapman, and F. Thalacker Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys J. Pharmacol. Exp. Ther. 324 2008 299 305
7. A.R. Diani, G. Sawada, B. Wyse, F.T. Murray, and M. Khan Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes Am. J. Physiol. Endocrinol. Metab. 286 2004 E116 E122
8. P. Ferrari The role of 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension Biochim. Biophys. Acta 1802 2010 1178 1187
9. T.C. Friedman, G. Mastorakos, T.D. Newman, N.M. Mullen, E.G. Horton, and R. Costello Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM Endocr. J. 43 1996 645 655
10. Y. Fukui, S. Masui, S. Osada, K. Umesono, and K. Motojima A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice Diabetes 49 2000 759 767
11. J.P. Gibbs, M.G. Emery, I. McCaffery, B. Smith, M.A. Gibbs, and A. Akrami Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activity after oral administration of AMG 221, a selective 11beta-HSD1 inhibitor J. Clin. Pharmacol. 51 2011 830 841
12. C. Hale, M. Veniant, Z. Wang, M. Chen, J. McCormick, and R. Cupples Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor Chem. Biol. Drug Des. 71 2008 36 44
13. A. Hermanowski-Vosatka, J.M. Balkovec, K. Cheng, H.Y. Chen, M. Hernandez, and G.C. Koo 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice J Exp. Med. 202 2005 517 527
14. A. Joharapurkar, N. Dhanesha, G. Shah, R. Kharul, and M. Jain 11beta-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome Pharmacol. Rep. 64 2012 1055 1065
15. R. Jones, D. Thurston, D. Rotella, S. Guccione, and A. Martinez New therapeutic strategies for type 2 diabetes: small molecule approaches RSC Drug Discov. 27 2012
16. C. Lambillotte, P. Gilon, and J.C. Henquin Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets J. Clin. Invest. 99 1997 414 423
17. D.E. Livingstone, G.C. Jones, K. Smith, P.M. Jamieson, R. Andrew, and C.J. Kenyon Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats Endocrinology 141 2000 560 563
18. H. Masuzaki, J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, and J.R. Seckl A transgenic model of visceral obesity and the metabolic syndrome Science 294 2001 2166 2170
19. Y. Momose, T. Maekawa, H. Odaka, H. Ikeda, and T. Sohda Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents Chem. Pharm. Bull. 50 2002 100 111
20. S.A. Morgan, and J.W. Tomlinson 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes Expert Opin. Investig. Drugs 19 2010 1067 1076
21. N.M. Morton Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease Mol. Cell. Endocrinol. 316 2010 154 164
22. N.M. Morton, J.M. Paterson, H. Masuzaki, M.C. Holmes, B. Staels, and C. Fievet Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice Diabetes 53 2004 931 938
23. A.J. Peckett, D.C. Wright, and M.C. Riddell The effects of glucocorticoids on adipose tissue lipid metabolism Metabolism 60 2011 1500 1510
24. C.D. Pereira, I. Azevedo, R. Monteiro, and M.J. Martins 11beta-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus Diabetes Obes. Metab. 14 2012 869 881
25. E. Rask, T. Olsson, S. Soderberg, R. Andrew, D.E. Livingstone, and O. Johnson Tissue-specific dysregulation of cortisol metabolism in human obesity J. Clin. Endocrinol. Metab. 86 2001 1418 1421
26. J. Rosenstock, S. Banarer, V.A. Fonseca, S.E. Inzucchi, W. Sun, and W. Yao The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy Diabetes Care 33 2010 1516 1522
27. T.C. Sandeep, R. Andrew, N.Z. Homer, R.C. Andrews, K. Smith, and B.R. Walker Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone Diabetes 54 2005 872 879
28. J.S. Scott, S.S. Bowker, J. Deschoolmeester, S. Gerhardt, D. Hargreaves, and E. Kilgour Discovery of a potent, selective, and orally bioavailable acidic 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acet ic acid (AZD4017) J. Med. Chem. 55 2012 5951 5964
29. J.R. Seckl, and B.R. Walker Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action Endocrinology 142 2001 1371 1376
30. B. Sorensen, M. Winn, J. Rohde, Q. Shuai, J. Wang, and S. Fung Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors Bioorg. Med. Chem. Lett. 17 2007 527 532
31. K. Srinivasan, and P. Ramarao Animal models in type 2 diabetes research: an overview Indian J. Med. Res. 125 2007 451 472
32. M. Sundbom, C. Kaiser, E. Bjorkstrand, V.M. Castro, C. Larsson, and G. Selen Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice BMC Pharmacol. 8 2008 3
33. Y. Tang, H. Osawa, H. Onuma, T. Nishimiya, M. Ochi, and H. Makino Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice Diabetes 48 1999 1830 1835
34. C.M. Tice, W. Zhao, P.M. Krosky, B.A. Kruk, J. Berbaum, and J.A. Johnson Discovery and optimization of adamantyl carbamate inhibitors of 11beta-HSD1 Bioorg. Med. Chem. Lett. 20 2010 6725 6729
35. M.E. Ullian, D.J. Hazen-Martin, L.G. Walsh, R.K. Davda, and B.M. Egan Carbenoxolone damages endothelium and enhances vasoconstrictor action in aortic rings Hypertension 27 1996 1346 1352
36. B.R. Walker, and J.R. Seckl 11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease Expert Opin. Ther. Targets 7 2003 771 783
37. Z.K. Wan, E. Chenail, J. Xiang, H.Q. Li, M. Ipek, and J. Bard Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model J. Med. Chem. 52 2009 5449 5461
38. M. Wang The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome Nutr. Metab. (Lond.) 2 2005 3